- Home
- ITHA vs SLGL Comparison
ITHA vs SLGL Comparison
Compare ITHA & SLGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ITHA | SLGL |
|---|---|---|
| Founded | 2025 | 1997 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 303.4M | 247.1M |
| IPO Year | N/A | 2016 |
Fundamental Metrics
Financial Performance| Metric | ITHA | SLGL |
|---|---|---|
| Price | $9.88 | $79.07 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $110.00 |
| AVG Volume (30 Days) | ★ 56.9K | 10.6K |
| Earning Date | 01-01-0001 | 04-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $122.71 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.87 | $0.40 |
| 52 Week High | $9.96 | $97.97 |
Technical Indicators
Market Signals| Indicator | ITHA | SLGL |
|---|---|---|
| Relative Strength Index (RSI) | 51.18 | 46.65 |
| Support Level | N/A | $71.01 |
| Resistance Level | $9.91 | $97.97 |
| Average True Range (ATR) | 0.01 | 11.44 |
| MACD | -0.00 | -2.26 |
| Stochastic Oscillator | 11.11 | 18.51 |
Price Performance
Historical ComparisonAbout ITHA ITHAX Acquisition Corp III Class A Ordinary Shares
ITHAX Acquisition Corp III is a blank check company formed for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses.
About SLGL Sol-Gel Technologies Ltd.
Sol-Gel Technologies Ltd is a dermatology company. It is engaged in identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. The company's product candidate pipeline includes SGT-610 (Patidegib Gel 2%), a new chemical entity hedgehog signaling pathway blocker, for the chronic use and prevention of new BCC in Gorlin syndrome patients, and the topical drug candidate SGT-210 for the treatment of Darier Disease and other rare keratosis-related indications such as PC, PPK and Olmsted.